Drug intelligence / Profile preview

PQM-214

Development stage: Preclinical
Modality: Small Molecules

Overview

PQM-214 is a synthetic curcumin-like small molecule compound investigated for its antineoplastic properties, particularly in lung adenocarcinoma. It exerts its effects by inducing cell cycle arrest, apoptosis, and cellular senescence. Mechanistically, PQM-214 modulates key cell cycle regulators, leading to the downregulation of MYC, FOXM1, and cyclins (E2 and B), while upregulating senescence markers such as p21 (CDKN1A) and Cyclin D1. Preclinical studies in A549 and other lung cancer cell lines have demonstrated its potential to inhibit proliferation and act as a possible senolytic agent.

Targets

TIMP1 (Metalloproteinase inhibitor 1)CCNB1 (Cyclin B1)MYC (MYC proto-oncogene protein)TIMP2FOXM1 (Forkhead box protein M1)CCNE2 (G1/S-specific cyclin-E2)

Beyond the preview

Go deeper on PQM-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PQM-214.

Explore the full profile